Journal profile · Biochemistry & Molecular Biology
Current Pharmaceutical Biotechnology
ISSN 1389-2010 · eISSN 1873-4316 · Bentham Science Publishers B.V. · UNITED STATES · Bimonthly · Founded 2000
Current Pharmaceutical Biotechnology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.76; subscription journal; median 93 days to acceptance (46 articles, last 24 months); community-reported acceptance: easy; 143 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Pharmaceutical Biotechnology is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are RNA Interference and Gene Delivery, Monoclonal and Polyclonal Antibodies Research and Nanoparticle-Based Drug Delivery, together about 21.9% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include: DNA/protein engineering and processing Synthetic biotechnology Omics (genomics, proteomics, metabolomics and systems biology) Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes) Drug delivery and targeting Nanobiotechnology Molecular pharmaceutics and molecular pharmacology Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes) Pharmacokinetics and pharmacodynamics Applied Microbiology Bioinformatics (computational biopharmaceutics and modeling) Environmental biotechnology Regenerative medicine (stem cells, tissue engineering and biomaterials) Translational immunology (cell therapies, antibody engineering, xenotransplantation) Industrial bioprocesses for drug production and development Biosafety Biotech ethics Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
Source: LetPub
Research area (LetPub): Biochemistry & Molecular Biology
Main research topics OpenAlex counts of recent articles; shares are approximate
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology8.4%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.9%
- Nanoparticle-Based Drug DeliveryMaterials Science6.6%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance5.9%
- Cancer Mechanisms and TherapyMedicine5.4%
- 14-3-3 protein interactionsBiochemistry, Genetics and Molecular Biology5.1%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics5%
- Computational Drug Discovery MethodsComputer Science4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.76LetPub ·
- CiteScore 2026-06
- 5.9LetPub ·
- SJR 2026-06
- 0.61LetPub ·
- SNIP 2026-06
- 0.63LetPub ·
- h-index
- 73LetPub ·
- h-index
- 114OpenAlex ·
- i10-index
- 1,757OpenAlex ·
- 2-year mean citedness
- 2.89OpenAlex ·
- Self-citation rate
- 6.9%LetPub ·
- Share of gold OA articles
- 1.38%LetPub ·
Volume
- Articles per year
- 159LetPub ·
Articles by year OpenAlex count · 3,457 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 111 | 4 | 27 |
| 2025 | 143 | 6 | 229 |
| 2024 | 215 | 10 | 1,098 |
| 2023 | 157 | 3 | 1,251 |
| 2022 | 159 | 7 | 1,688 |
| 2021 | 192 | 22 | 2,272 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
93 daysMedian, submission to acceptance · P25–P75 75 days – 111 days
- Acceptance to online
- median 144 days (46 articles)
- Submission to online
- median 224 days
- Sample
- 46 articles with submission and acceptance dates (470 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–6 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2000
- ISSN
- 1389-2010
- Electronic ISSN
- 1873-4316
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Pharmaceutical Biotechnology
What CAS zone is Current Pharmaceutical Biotechnology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Pharmaceutical Biotechnology is in Zone 4 of Medicine, and in Zone 4 of the minor category Biochemistry & Molecular Biology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Pharmaceutical Biotechnology?
The latest impact factor listed by LetPub is 2.76; CiteScore 5.9, h-index 114.
How long does peer review take at Current Pharmaceutical Biotechnology?
Based on the dates recorded on 46 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 93 days (interquartile range 75–111 days); authors report an average review time of 3–6 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Pharmaceutical Biotechnology?
According to LetPub and DOAJ records, Current Pharmaceutical Biotechnology is indexed in SCIE and Scopus.
Is Current Pharmaceutical Biotechnology open access, and what is the APC?
Current Pharmaceutical Biotechnology is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .